SPC365

Cardiac Rehabilitation Phase 3 - Who are those who continue down the path?

Session: Posters (Sessão 5 - Écran 8) - Reabilitação cardíaca
Speaker: Diogo Rosa Ferreira

Congress: CPC 2023
Topic: J. Preventive Cardiology
Theme: 29. Rehabilitation and Sports Cardiology
Subtheme: 29.2 Cardiovascular Rehabilitation
Session Type: Pósters Electrónicos
FP Number: ---
Authors: Diogo Ferreira; Pedro Alves da Silva; Joana Brito; Beatriz Silva; Marta Vilela; Daniel Cazeiro; João Cravo; Beatriz Garcia; Catarina Oliveira; Paula Sousa; Nelson Cunha; Inês Ricardo; Rita Pinto; Fausto J. Pinto; Ana Abreu

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Introduction</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000">: Cardiac Rehabilitation is recommended as secondary prevention in patients (pts) with cardiovascular disease. Efforts to increase referral of patients after hospitalisations have been made in order to increase adherence to phase 2 CR programs. However, there are still few data regarding adherence after completion of phase 2 programs regarding progressing to phase 3 programs.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Purpose</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000">: To characterize a population of patients who enrolled in a phase 3 CR program.</span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Methods</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000">: </span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff">Prospective cohort study which included consecutive pts who were participating in a center-based CR program lasting 8-12 weeks from 2019 to 2021. We analyzed the prevalence of risk factors, lab echocardiographic and CPET data at the beginning and 6 months after FUP. Possibility of attendance of a phase III CR program on a nearby gym was offered to everyone.&nbsp; Statistical analysis between both groups was performed with Chi-Square and Wilcoxon tests.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff"><strong>Results: </strong></span></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff">We analyzed 336 patients who underwent CR (82% male, mean age 60 &plusmn;11,4 years). The majority was referred for ischemic heart disease (83%) followed by valvular heart disease (7%). Mean follow-up was 36,7</span></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000">&plusmn;</span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff"> 19,2 months. Phase 3 program in a nearby facility was offered to everyone. Of those, 217 pts (mean age 59 +- 11,4 years-old, 80% male) chose not to continue and 119 pts (mean age 61 +- 11,3 years old, 81% male) were enrolled in the program. There were some differences among the two groups: ischemic heart disease was more prevalent in those who didn&rsquo;t progress to Phase III (83% vs 66%, p=0.02) and, regarding risk factors, we noted a higher prevalence among those who enrolled in phase III, namely hypertension (77% vs 88%, p=0.04) and previous smoking habits (64,2% vs 71,1%, p=0.02). There were no significant differences regarding lab and echo data at the end of the program, especially ejection fraction, NTproBNP and LDL cholesterol. We failed to find differences between CPET data after 6 months follow up, although such findings might be limited by the scarcity of data in the group who transitioned to phase III.</span></span></span></span></p>

<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff"><strong>Conclusions: </strong></span></span></span></span><span style="font-size:12pt"><span style="font-family:Arial"><span style="color:#000000"><span style="background-color:#ffffff">Patients with a higher burden of risk factors showed higher interest in progressing to a phase III program. We did not find differences in cardiorespiratory fitness evaluated by CPET, although more robust data would be needed to back such observations.&nbsp;</span></span></span></span></p>

<p>&nbsp;</p>